Shots:

• The 2nd P-III (Study 0170) evaluates ampreloxetine vs PBO in patients with symptomatic nOH. The 1EPs were treatment failure @6wks. & showed no significant results for the overall population including patients with PD, PAF & MSA, 40% reduction in odds of treatment failure, was well-tolerated with no new safety signals
• In prespecified subgroup analysis, the results showed a benefit in patients with MSA, 72% reduction in odds of treatment failure
• Patients withdrawn to PBP had a relevant decrease in standing blood pressure, no worsening of supine hypertension, following 24hr. monitoring. The company plans to discuss with strategic partners & health authorities to advance ampreloxetine for symptomatic nOH

Ref: Theravance | Image: Theravance